Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hypertension

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 77 articles:
HTML format



Single Articles


    August 2020
  1. SCHWALM JD, McCready T, Islam S, McKee M, et al
    Cardiovascular risk in hypertension: open questions about HOPE 4 - Authors' reply.
    Lancet. 2020;396:310-311.
    PubMed    


  2. RICHARDS A
    Cardiovascular risk in hypertension: open questions about HOPE 4.
    Lancet. 2020;396:310.
    PubMed    


  3. HENDRIKS M, van Andel J, Asiki G, Kyobutungi C, et al
    Cardiovascular risk in hypertension: open questions about HOPE 4.
    Lancet. 2020;396:309-310.
    PubMed    


  4. O'SULLIVAN ED, MacIntyre IM
    Individual patient risk assessment and cost-benefit analysis of patiromer in AMBER.
    Lancet. 2020;396:311.
    PubMed    


    July 2020
  5. CLUVER CA, Herbst P, Griffith-Richards S, Hassan M, et al
    Coarctation of the aorta: a rare cause of severe hypertension in pregnancy.
    Lancet. 2020;396:62.
    PubMed    


  6. REGAN J
    Collaborating on kidneys: Haiti's transplantation ambitions.
    Lancet. 2020;396:15-16.
    PubMed    


    June 2020
  7. STRONGMAN H, Lyon AR, Dos Santos Silva I, Smeeth L, et al
    Cancer and cardiovascular disease - Authors' reply.
    Lancet. 2020;395:1904-1905.
    PubMed    


  8. AHMED MA, Abdelnabi M, Almaghraby A, Elkafrawy FR, et al
    Neuropathy, encephalopathy, status epilepticus, and acute intermittent porphyria.
    Lancet. 2020;395:e101.
    PubMed    


    May 2020
  9. WILLIAMS B, Zhang Y
    Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19.
    Lancet. 2020 May 14. pii: S0140-6736(20)31131.
    PubMed    


    March 2020
  10. BOHM M, Kario K, Kandzari DE, Mahfoud F, et al
    Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial.
    Lancet. 2020 Mar 27. pii: S0140-6736(20)30554.
    PubMed     Abstract available


  11. HERRETT E, Jackson R, Smeeth L
    Managing cardiovascular disease risk in hypertension - Authors' reply.
    Lancet. 2020;395:870.
    PubMed    


  12. MCMANUS R, Constanti M, Floyd CN, Glover M, et al
    Managing cardiovascular disease risk in hypertension.
    Lancet. 2020;395:869-870.
    PubMed    


  13. ZHOU F, Yu T, Du R, Fan G, et al
    Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
    Lancet. 2020 Mar 11. pii: S0140-6736(20)30566.
    PubMed     Abstract available


    November 2019
  14. IVES CW, Oparil S
    What is the first choice for blood pressure treatment?
    Lancet. 2019;394:1782-1784.
    PubMed    


    October 2019
  15. GANESAN C, Pao AC
    Spironolactone plus patiromer: proceed with caution.
    Lancet. 2019;394:1486-1488.
    PubMed    


  16. THE LANCET
    Where next for randomised controlled trials in global health?
    Lancet. 2019;394:1481.
    PubMed    


  17. SUCHARD MA, Schuemie MJ, Krumholz HM, You SC, et al
    Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.
    Lancet. 2019 Oct 24. pii: S0140-6736(19)32317.
    PubMed     Abstract available


    September 2019
  18. ZHOU M, Wang H, Zeng X, Yin P, et al
    Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet. 2019;394:1145-1158.
    PubMed     Abstract available


  19. AGARWAL R, Rossignol P, Romero A, Garza D, et al
    Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
    Lancet. 2019 Sep 13. pii: S0140-6736(19)32135.
    PubMed     Abstract available


  20. THE LANCET
    NICE hypertension guidelines: a pragmatic compromise.
    Lancet. 2019;394:806.
    PubMed    


  21. YUSUF S, Joseph P, Rangarajan S, Islam S, et al
    Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.
    Lancet. 2019 Sep 2. pii: S0140-6736(19)32008.
    PubMed     Abstract available


    August 2019
  22. SCHWALM JD, McCready T, Lopez-Jaramillo P, Yusoff K, et al
    A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31949.
    PubMed     Abstract available


  23. JAFAR TH, Samad Z, Bloomfield GS
    Parallel community solutions for cardiovascular risk reduction.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31995.
    PubMed    


  24. THE LANCET
    Is the concept of hypertension as a disease unhelpful?
    Lancet. 2019;394:611.
    PubMed    


  25. CHOW CK, Gupta R
    Blood pressure control: a challenge to global health systems.
    Lancet. 2019;394:613-615.
    PubMed    


  26. LEMOINE ER, Karumanchi SA
    Oral regimen management of acute hypertension in pregnancy.
    Lancet. 2019 Aug 1. pii: S0140-6736(19)31717.
    PubMed    


  27. EASTERLING T, Mundle S, Bracken H, Parvekar S, et al
    Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial.
    Lancet. 2019 Aug 1. pii: S0140-6736(19)31282.
    PubMed     Abstract available


    July 2019
  28. KAHAN T
    Strategies to identify patients for antihypertensive treatment.
    Lancet. 2019 Jul 25. pii: S0140-6736(19)31665.
    PubMed    


  29. HERRETT E, Gadd S, Jackson R, Bhaskaran K, et al
    Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study.
    Lancet. 2019 Jul 25. pii: S0140-6736(19)31359.
    PubMed     Abstract available


  30. GELDSETZER P, Manne-Goehler J, Marcus ME, Ebert C, et al
    The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults.
    Lancet. 2019 Jul 18. pii: S0140-6736(19)30955.
    PubMed     Abstract available



  31. Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys.
    Lancet. 2019 Jul 18. pii: S0140-6736(19)31145.
    PubMed     Abstract available


  32. BENJAMIN IJ, Kreutz R, Olsen MH, Schutte AE, et al
    Fixed-dose combination antihypertensive medications.
    Lancet. 2019 Jul 15. pii: S0140-6736(19)31629.
    PubMed    


    May 2019
  33. FUDIM M, Ali-Ahmed F, Patel MR, Sobotka PA, et al
    Sham trials: benefits and risks for cardiovascular research and patients.
    Lancet. 2019;393:2104-2106.
    PubMed    


    April 2019
  34. DUHIG KE, Myers J, Seed PT, Sparkes J, et al
    Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial.
    Lancet. 2019 Apr 1. pii: S0140-6736(18)33212.
    PubMed     Abstract available


    March 2019
  35. MENTE A, O'Donnell MJ, Yusuf S
    Urinary sodium excretion measures and health outcomes - Authors' reply.
    Lancet. 2019;393:1295-1296.
    PubMed    


  36. VILLANUEVA C, Albillos A, Genesca J, Garcia-Pagan JC, et al
    beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Lancet. 2019 Mar 22. pii: S0140-6736(18)31875.
    PubMed     Abstract available


  37. GAZZARD G, Konstantakopoulou E, Garway-Heath D, Garg A, et al
    Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial.
    Lancet. 2019 Mar 8. pii: S0140-6736(18)32213.
    PubMed     Abstract available


    February 2019

  38. Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial.
    Lancet. 2019 Feb 5. pii: S0140-6736(19)30194.
    PubMed     Abstract available


    December 2018
  39. YOUSEFIFARD M, Hosseini M
    Should the cutoff for hypertension in older adults be different from younger adults?
    Lancet. 2018;392:2438-2439.
    PubMed    


    November 2018
  40. OLIVA-DAMASO N, Costa-Fernandez J, Oliva-Damaso E, Bravo-Marques R, et al
    Kidneys are key in secondary hypertension: a case of fibromuscular dysplasia.
    Lancet. 2018;392:2298.
    PubMed    


    October 2018
  41. LU J, Lu Y, Krumholz HM, Jiang L, et al
    Prevalence and control of hypertension - Authors' reply.
    Lancet. 2018;392:1306.
    PubMed    


  42. BOVET P, Chiolero A
    Prevalence and control of hypertension.
    Lancet. 2018;392:1305-1306.
    PubMed    


  43. CORDONNIER C, Demchuk A, Ziai W, Anderson CS, et al
    Intracerebral haemorrhage: current approaches to acute management.
    Lancet. 2018;392:1257-1268.
    PubMed     Abstract available


    September 2018
  44. OPARIL S, Fu RH
    Revisiting ASCOT 16 years later.
    Lancet. 2018;392:1092-1094.
    PubMed    


  45. KISHORE SP, Salam A, Rodgers A, Jaffe MG, et al
    Fixed-dose combinations for hypertension.
    Lancet. 2018;392:819-820.
    PubMed    


    August 2018
  46. GUPTA A, Mackay J, Whitehouse A, Godec T, et al
    Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31776.
    PubMed     Abstract available


    July 2018
  47. HE FJ, Zhang P, Li Y, MacGregor GA, et al
    Action on Salt China.
    Lancet. 2018;392:7-9.
    PubMed    


    June 2018
  48. KJELDSEN SE, Esler MD
    Take a blood pressure pill or undergo renal denervation?
    Lancet. 2018;391:2298-2300.
    PubMed    


    May 2018
  49. BLANKESTIJN PJ, Bots ML
    Renal denervation in uncontrolled hypertension: the story continues to unfold.
    Lancet. 2018 May 22. pii: S0140-6736(18)31112.
    PubMed    


  50. AZIZI M, Schmieder RE, Mahfoud F, Weber MA, et al
    Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.
    Lancet. 2018 May 22. pii: S0140-6736(18)31082.
    PubMed     Abstract available


  51. KANDZARI DE, Bohm M, Mahfoud F, Townsend RR, et al
    Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.
    Lancet. 2018 May 22. pii: S0140-6736(18)30951.
    PubMed     Abstract available


    February 2018
  52. RIETZSCHEL ER, De Buyzere ML
    Hypertension: time for doctors to switch the driver's seat?
    Lancet. 2018 Feb 27. pii: S0140-6736(18)30317.
    PubMed    


  53. MCMANUS RJ, Mant J, Franssen M, Nickless A, et al
    Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial.
    Lancet. 2018 Feb 27. pii: S0140-6736(18)30309.
    PubMed     Abstract available


    January 2018
  54. CHAKER L, Bianco AC, Jonklaas J, Peeters RP, et al
    Hypothyroidism and hypertension: fact or myth? - Authors' reply.
    Lancet. 2018;391:30.
    PubMed    


  55. HOFSTETTER L, Messerli FH
    Hypothyroidism and hypertension: fact or myth?
    Lancet. 2018;391:29-30.
    PubMed    


    October 2017
  56. SU M, Zhang Q, Bai X, Wu C, et al
    Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey.
    Lancet. 2017 Oct 25. pii: S0140-6736(17)32476.
    PubMed     Abstract available


  57. HESKETH T, Zhou X
    Hypertension in China: the gap between policy and practice.
    Lancet. 2017 Oct 25. pii: S0140-6736(17)32743.
    PubMed    


  58. LU J, Lu Y, Wang X, Li X, et al
    Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project).
    Lancet. 2017 Oct 25. pii: S0140-6736(17)32478.
    PubMed     Abstract available


    September 2017
  59. SPIERING W, Williams B, Van der Heyden J, van Kleef M, et al
    Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study.
    Lancet. 2017 Sep 1. pii: S0140-6736(17)32337.
    PubMed     Abstract available


  60. COURAND PY, Lantelme P
    Stretching the carotid sinus to treat resistant hypertension.
    Lancet. 2017 Sep 1. pii: S0140-6736(17)32298.
    PubMed    


    August 2017
  61. AZIZI M
    Catheter-based renal denervation for treatment of hypertension.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32293.
    PubMed    


  62. TOWNSEND RR, Mahfoud F, Kandzari DE, Kario K, et al
    Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32281.
    PubMed     Abstract available


    July 2017
  63. RODGERS A, Chow CK, Thakkar J, Bennett A, et al
    A personalised or procrustean approach to treating hypertension? - Authors' reply.
    Lancet. 2017;390:27-28.
    PubMed    


  64. GABB GM, Mol PGM, Arnolda LF
    A personalised or procrustean approach to treating hypertension?
    Lancet. 2017;390:26-27.
    PubMed    


    June 2017
  65. MUNDLE S, Bracken H, Khedikar V, Mulik J, et al
    Foley catheterisation versus oral misoprostol for induction of labour in hypertensive women in India (INFORM): a multicentre, open-label, randomised controlled trial.
    Lancet. 2017 Jun 28. pii: S0140-6736(17)31367.
    PubMed     Abstract available


  66. SURI V, Sikka P
    Oral misoprostol for induction of labour in hypertensive pregnancies.
    Lancet. 2017 Jun 28. pii: S0140-6736(17)31453.
    PubMed    


    April 2017
  67. VIDAL-PETIOT E, Bhatt DL, Fox KM, Steg PG, et al
    Blood pressure and cardiovascular outcomes: a closer look - Authors' reply.
    Lancet. 2017;389:1296-1297.
    PubMed    


  68. WALD NJ, Wald DS
    Blood pressure and cardiovascular outcomes: a closer look.
    Lancet. 2017;389:1296.
    PubMed    


  69. DOUMAS M, Stavropoulos KV, Boutari C, Imprialos KP, et al
    Blood pressure and cardiovascular outcomes: a closer look.
    Lancet. 2017;389:1295-1296.
    PubMed    


    December 2016
  70. SLIWA K
    The heart of Africa: succeeding against the odds.
    Lancet. 2016;388:e28-e36.
    PubMed     Abstract available


    October 2016
  71. MENTE A, O'Donnell MJ, Yusuf S
    Sodium and cardiovascular disease - Authors' reply.
    Lancet. 2016;388:2113-2114.
    PubMed    


  72. CAPPUCCIO FP
    Sodium and cardiovascular disease.
    Lancet. 2016;388:2112.
    PubMed    


  73. KATZ J
    Sodium and cardiovascular disease.
    Lancet. 2016;388:2112-2113.
    PubMed    


  74. STRAZZULLO P, Giampaoli S, Iacoviello L, Rossi L, et al
    Sodium and cardiovascular disease.
    Lancet. 2016;388:2111.
    PubMed    


  75. WALD N, Law M
    Sodium and cardiovascular disease.
    Lancet. 2016;388:2111-2112.
    PubMed    


  76. ALDERMAN MH
    Dietary sodium: paradigm shifts from public health to clinical medicine.
    Lancet. 2016;388:2110.
    PubMed    


    August 2016
  77. VIDAL-PETIOT E, Ford I, Greenlaw N, Ferrari R, et al
    Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31326.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hypertension is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: